Syros Pharmaceuticals Inc (NASDAQ:SYRS) Given Consensus Rating of “Buy” by Analysts

Syros Pharmaceuticals Inc (NASDAQ:SYRS) has been assigned a consensus rating of “Buy” from the eleven analysts that are presently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $16.46.

A number of research analysts recently weighed in on SYRS shares. ValuEngine lowered shares of Yirendai from a “sell” rating to a “strong sell” rating in a research report on Wednesday, June 26th. BidaskClub raised shares of Westport Fuel Systems from a “hold” rating to a “buy” rating in a research report on Friday. Wedbush reissued an “outperform” rating on shares of Alphabet in a research report on Thursday, April 25th. Zacks Investment Research lowered shares of Farmers & Merchants Bancorp, Inc. (OH) from a “hold” rating to a “strong sell” rating in a research report on Thursday, May 9th. Finally, Piper Jaffray Companies set a $44.00 price target on shares of First Merchants and gave the company a “buy” rating in a research report on Wednesday, April 10th.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Northern Trust Corp increased its holdings in Syros Pharmaceuticals by 0.7% during the fourth quarter. Northern Trust Corp now owns 306,167 shares of the company’s stock worth $1,705,000 after buying an additional 2,179 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. increased its holdings in Syros Pharmaceuticals by 8.3% during the first quarter. Los Angeles Capital Management & Equity Research Inc. now owns 40,380 shares of the company’s stock worth $369,000 after buying an additional 3,100 shares during the last quarter. Alps Advisors Inc. increased its holdings in Syros Pharmaceuticals by 4.5% during the first quarter. Alps Advisors Inc. now owns 81,287 shares of the company’s stock worth $743,000 after buying an additional 3,519 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its holdings in Syros Pharmaceuticals by 3.3% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 122,561 shares of the company’s stock worth $683,000 after buying an additional 3,900 shares during the last quarter. Finally, BNP Paribas Arbitrage SA purchased a new stake in Syros Pharmaceuticals during the first quarter worth about $48,000. Institutional investors and hedge funds own 56.16% of the company’s stock.

Shares of Syros Pharmaceuticals stock traded up $0.17 during trading hours on Friday, reaching $8.75. The company’s stock had a trading volume of 8,270 shares, compared to its average volume of 290,944. Syros Pharmaceuticals has a one year low of $5.17 and a one year high of $13.18. The stock has a market cap of $362.39 million, a P/E ratio of -4.61 and a beta of 1.95. The business has a fifty day simple moving average of $6.98. The company has a quick ratio of 5.19, a current ratio of 5.19 and a debt-to-equity ratio of 0.02.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings data on Wednesday, May 1st. The company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.08. Syros Pharmaceuticals had a negative net margin of 3,012.04% and a negative return on equity of 74.28%. The firm had revenue of $0.45 million for the quarter, compared to analyst estimates of $0.42 million. As a group, equities analysts forecast that Syros Pharmaceuticals will post -1.82 earnings per share for the current year.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.

Read More: Capital Gains

Analyst Recommendations for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.